Praziquantel + Albendazole pharmacokinetic interaction

The Praziquantel + Albendazole pharmacokinetic interaction refers to the metabolic synergy that occurs when these two anthelmintic agents are co-administered, a common practice in treating polyparasitism and neurocysticercosis. This interaction is not a single molecular target but a clinical phenomenon where albendazole significantly enhances the bioavailability of praziquantel. Studies have shown that the peak plasma concentration (Cmax) and the area under the curve (AUC) of praziquantel can increase by nearly 50% to 100% when given alongside albendazole (Jung et al., 1990, PubMed: 2334075). This effect is attributed to the modulation of hepatic enzymes, specifically the Cytochrome P450 isoforms CYP3A4 and CYP1A2, which are responsible for the extensive first-pass metabolism of praziquantel. While this interaction can improve the therapeutic efficacy against certain helminths, it also heightens the risk of dose-dependent side effects. Consequently, understanding this interaction is vital for optimizing treatment protocols in global health initiatives targeting parasitic diseases.

Other names

Praziquantel-Albendazole drug interactionPZQ-ABZ interactionAnthelmintic drug-drug interaction

The interaction is primarily mediated through the Cytochrome P450 enzyme system. Albendazole (or its active metabolite albendazole sulfoxide) increases the plasma concentration and bioavailability of praziquantel by inhibiting its first-pass metabolism, likely involving CYP3A4 and CYP1A2 (Sotelo et al., 1990, PubMed: 2102117). Additionally, praziquantel has been observed to increase the plasma levels of albendazole sulfoxide in some clinical settings (Homeida et al., 1994, PubMed: 7995011).